Incyte (NASDAQ: INCY) shareholders had a rough Thursday, with shares dropping about 10% on Thursday and another 3% Friday after ASCO abstracts were published. Jakafi, Incyte's myelofibrosis drug partnered with Johnson & Johnson, underperformed -- it failed to generate a statistically significant increase in progression-free survival or overall survival in a trial for pancreatic cancer patients.

The drug did show some clinical benefit in overall survival for a previously defined patient subgroup, with overall survival at 3 and 6 months of 48% and 42%, vs 29% and 11% for the control. Jakafi is in clinical trials for a number of other potential oncology indications -- was the drop overdone?

In this video, from Market Checkup, the Motley Fool's health care focused investing show, health care analysts Michael Douglass and David Williamson discuss the data results and key takeaways for investors.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson and The Motley Fool own shares of Johnson & Johnson, and The Motley Fool recommends Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.